Related Experiment Video
Updated: Jun 16, 2026

The WATCHMAN Left Atrial Appendage Closure Device for Atrial Fibrillation
Published on: February 28, 2012
Dual antiplatelet therapy is not optimal for stroke prevention in patients with atrial fibrillation
1Comprehensive Stroke Center, Hospital Clinic, University of Barcelona, Institut d'Investigacions Biomèdiques August Pi i Sunyer, Barcelona, Spain. achamorro@ub.edu
Insights
Dual antiplatelet therapy with clopidogrel and aspirin shows reduced stroke risk but increased bleeding in atrial fibrillation patients. Oral anticoagulation remains superior despite its risks.
Area of Science:
- Cardiology
- Neurology
- Pharmacology
Background:
- Oral anticoagulation is effective for stroke prevention in atrial fibrillation but carries bleeding risks and interactions.
- Dual antiplatelet therapy (DAPT) offers an alternative, with studies like ACTIVE A evaluating its efficacy.
Purpose of the Study:
- To critically analyze the role of dual antiplatelet therapy in preventing recurrent stroke for patients diagnosed with atrial fibrillation.
Main Methods:
- The ACTIVE A trial assessed dual antiplatelet therapy (clopidogrel plus aspirin) versus aspirin monotherapy.
- Comparative analysis of primary event rates and major bleeding risks between treatment groups.
Main Results:
- Dual antiplatelet therapy significantly reduced the relative risk of primary thrombotic events compared to aspirin alone.
- However, dual antiplatelet therapy also significantly increased the relative risk of major bleeding events.
Conclusions:
- While DAPT shows efficacy in reducing thrombotic events, the increased bleeding risk necessitates careful consideration.
- The established benefits of oral anticoagulation for stroke prevention in atrial fibrillation warrant continued evaluation against DAPT's risk-benefit profile.
Abstract:
The superior efficacy of oral anticoagulation over aspirin for prevention of recurrent stroke in patients with atrial fibrillation is widely acknowledged. However, oral anticoagulation therapy is notorious for having a narrow therapeutic index, numerous drug and dietary interactions, and a significant risk of serious bleeding. The value of dual antiplatelet therapy for stroke prevention in patients with atrial fibrillation has been assessed in the ACTIVE A trial. In this study, the relative risk of primary events was significantly decreased in patients allocated clopidogrel and aspirin compared with patients receiving aspirin alone. However, the relative risk of major bleeding was also significantly increased. This article analyses critically the role of dual antiplatelet therapy for stroke prevention in patients with atrial fibrillation.
Related Concept Videos
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Venous Thrombosis III: Interprofessional Care
Anticoagulant Drugs: Low-Molecular-Weight Heparins
Coronary Artery Disease V: Interprofessional Care
Peripheral Artery Disease III: Interprofessional Care
